ClinicalTrials.Veeva

Find clinical trials for Melanoma in Pittsburgh, PA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near Pittsburgh, PA, USA:

A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma

The purpose of this study is to evaluate the effectiveness and safety of the combination of Pembrolizumab (KEYTRUDA®) and the investigational drug, M...

Enrolling
Advanced Melanoma
Drug: Metformin
Drug: Pembrolizumab Injection [Keytruda]

Phase 1

Yana Najjar

Pittsburgh, Pennsylvania, United States

ATLAS-IT-05 is an open-label, single-arm study in patients with advanced melanoma accessible for injections (cutaneous, subcutaneous, lymph ...

Active, not recruiting
Advanced Melanoma
Combination Product: LTX-315 in combination with pembrolizumab

Phase 2

Lytix Biopharma

Pittsburgh, Pennsylvania, United States and 9 other locations

Locations recently updated

alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...

Enrolling
Melanoma
Unresectable Melanoma
Biological: Pembrolizumab with Optional Crossover Period
Biological: Lifileucel plus Pembrolizumab

Phase 3

Iovance Biotherapeutics

Pittsburgh, Pennsylvania, United States and 32 other locations

therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma...

Enrolling
Advanced Melanoma
Drug: Tebentafusp with Pembrolizumab
Drug: Tebentafusp

Phase 2, Phase 3

Immunocore
Immunocore

Pittsburgh, Pennsylvania, United States and 70 other locations

Patients with unresectable or metastatic BRAF-mutant melanoma high-risk patients will be given 450 mg orally (PO) daily (QD) plus binimetini...

Active, not recruiting
Melanoma
Drug: encorafenib
Drug: ipilimumab

Phase 1, Phase 2

Jason J. Luke, MD

Pittsburgh, Pennsylvania, United States

This early-phase study will examine Vusolimogene Oderparepvec, a genetically modified oncolytic viral strain of the herpes simplex type 1 (HSV-1) vir...

Enrolling
Melanoma
Biological: Vusolimogene oderparepvec (RP1)

Early Phase 1

Yana Najjar

Pittsburgh, Pennsylvania, United States

This is Phase II trial of nivolumab plus axitinib for patients with unresectable stage III or IV melanoma who have progressed on prior anti-...

Active, not recruiting
Advanced Melanoma
Unresectable Melanoma
Drug: Axitinib
Drug: Nivolumab

Phase 2

Yana Najjar

Pittsburgh, Pennsylvania, United States

To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investiga...

Active, not recruiting
Uveal Melanoma
Biological: IMCgp100
Biological: Pembrolizumab

Phase 2

Immunocore
Immunocore

Pittsburgh, Pennsylvania, United States and 55 other locations

Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin...

Active, not recruiting
Metastatic Melanoma
Biological: Lifileucel

Phase 2

Iovance Biotherapeutics

Pittsburgh, Pennsylvania, United States and 56 other locations

A*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomark...

Begins enrollment in 1 month
Uveal Melanoma
Drug: Tebentafusp

Phase 2

Diwakar Davar

Pittsburgh, Pennsylvania, United States

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems